Gastric bypass surgery can improve glycemic control in adults with type 2 diabetes, but doesn't cure diabetes, according to the largest community-based study of long-term diabetes outcomes after bariatric surgery, published online ahead of print in Obesity Surgery.
Gastric bypass surgery can improve glycemic control in adults with type 2 diabetes, but doesn’t cure diabetes, according to the largest community-based study of long-term diabetes outcomes after bariatric surgery, published online ahead of print in Obesity Surgery.
The multisite study tracked 4,434 adults at Kaiser Permanente Northern California, Kaiser Permanente Southern California, and HealthPartners from 1995 to 2008. The research arms of all 3 of these integrated healthcare delivery systems-and Group Health Research Institute, where the study’s results were analyzed-belong to the HMO Research Network. The patients had type 2 diabetes that was either controlled with medication or else uncontrolled, and they were also obese enough to be candidates for gastric bypass surgery.
“We found that for most of those people, diabetes either never remitted after gastric surgery or relapsed within 5 years,” principal investigator David E. Arterburn, MD, MPH, a general internist and associate investigator at Group Health Research Institute, in Seattle, told Formulary.
The main impetus of the study is the growing numbers of Americans who are obese and have type 2 diabetes, according to Dr Arterburn. “Also, researchers have been disappointed with the results from attempts to treat diabetes with intensive lifestyle changes and intensive medical management,” he said.
Meanwhile, prior research has shown that, at least in the short term, gastric bypass surgery can profoundly improve glycemic control in adults with type 2 diabetes-often even before they lose significant weight. “That led some people to think that gastric bypass surgery might be a ‘cure’ for diabetes,” Dr Arterburn explained. “But we wanted to see what happened in the longer term.”
It’s still not clear whether diabetes relapse happens because of gaining weight back or because of the underlying progression of diabetes. But patients’ weight-before and after surgery-was not strongly correlated with remission or relapse of diabetes in this population.
“Managed care and hospital decision-makers need to find the best ways to care for their many patients who are obese and have diabetes-ways that will serve those patients best in the long run,” Dr Arterburn said. “Of course prevention is the best medicine. And gastric bypass surgery isn’t for everyone. But for patients who are already obese and have diabetes, our results suggest that it’s never too early to start considering the surgery.
“Our results suggest that, after gastric surgery, diabetes remits for longer in those people whose diabetes was less severe and at an earlier stage when they had the surgery,” he added. â
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More